Cargando…

Pharmacokinetic/Pharmacodynamic Integration of Doxycycline Against Mycoplasma hyopneumoniae in an In Vitro Model

Doxycycline is a broad-spectrum antibacterial drug. It is used widely to treat diseases caused by Mycoplasma species. We investigated the antibacterial activity of doxycycline against the Mycoplasma hyopneumoniae strain ATCC25934. The minimum inhibitory concentration (MIC) of doxycycline against M....

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Huilin, Mao, Chunxiao, Li, Jinju, Huang, Zilong, Gu, Xiaoyan, Shen, Xiangguang, Ding, Huanzhong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6763577/
https://www.ncbi.nlm.nih.gov/pubmed/31620004
http://dx.doi.org/10.3389/fphar.2019.01088
_version_ 1783454226524930048
author Zhang, Huilin
Mao, Chunxiao
Li, Jinju
Huang, Zilong
Gu, Xiaoyan
Shen, Xiangguang
Ding, Huanzhong
author_facet Zhang, Huilin
Mao, Chunxiao
Li, Jinju
Huang, Zilong
Gu, Xiaoyan
Shen, Xiangguang
Ding, Huanzhong
author_sort Zhang, Huilin
collection PubMed
description Doxycycline is a broad-spectrum antibacterial drug. It is used widely to treat diseases caused by Mycoplasma species. We investigated the antibacterial activity of doxycycline against the Mycoplasma hyopneumoniae strain ATCC25934. The minimum inhibitory concentration (MIC) of doxycycline against M. hyopneumoniae determined by a microdilution method was 0.125 μg/ml. Static time–kill curves with constant drug concentrations (0–64 MIC) showed that a bacteriostatic effect occurred if the doxycycline concentration reached 4 MIC. Doxycycline produced a maximum antimycoplasmal effect (reduction of 2.76 log(10)CFU/ml) at 64 MIC within 48 h. The effect of doxycycline against M. hyopneumoniae was analyzed by a sigmoid E (max) model, and there was high correlation between the kill rate and doxycycline concentration (R (2) = 0.986). A one-compartment open model with first-order absorption was adopted and was used to simulate doxycycline pharmacokinetics in porcine plasma. The dynamic time–concentration curve showed that the area under the curve at 24 h (AUC(24 h)) and C (max) (peak concentration) after each drug administration was 1.78–48.4 μg h/ml and 0.16–3.41 μg/ml, respectively. The reduction of M. hyopneumoniae (log(10)CFU/ml) for 1, 2.5, 5, 7.5, 10, 15, 20, and 30 mg/kg body weight was 0.16, 1.29, 1.75, 2.94, 3.35, 3.91, 4.35, and 5.77, respectively, during the entire experiment, respectively. When the dose was >10 mg/kg body weight, continuous administration for 3 days could achieve a bactericidal effect. The correlation coefficient of AUC(24 h)/MIC, C (max)/MIC, and %T > MIC (the cumulative percentage of time over a 24-h period that the drug concentration exceeds the MIC) with antibacterial effect was 0.917, 0.923, and 0.823, respectively. Doxycycline showed concentration-dependent activity, and the value of AUC(24 h)/MIC and C (max)/MIC required to produce a drop of 1 log(10)CFU/ml was 164 h and 9.89, respectively.
format Online
Article
Text
id pubmed-6763577
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-67635772019-10-16 Pharmacokinetic/Pharmacodynamic Integration of Doxycycline Against Mycoplasma hyopneumoniae in an In Vitro Model Zhang, Huilin Mao, Chunxiao Li, Jinju Huang, Zilong Gu, Xiaoyan Shen, Xiangguang Ding, Huanzhong Front Pharmacol Pharmacology Doxycycline is a broad-spectrum antibacterial drug. It is used widely to treat diseases caused by Mycoplasma species. We investigated the antibacterial activity of doxycycline against the Mycoplasma hyopneumoniae strain ATCC25934. The minimum inhibitory concentration (MIC) of doxycycline against M. hyopneumoniae determined by a microdilution method was 0.125 μg/ml. Static time–kill curves with constant drug concentrations (0–64 MIC) showed that a bacteriostatic effect occurred if the doxycycline concentration reached 4 MIC. Doxycycline produced a maximum antimycoplasmal effect (reduction of 2.76 log(10)CFU/ml) at 64 MIC within 48 h. The effect of doxycycline against M. hyopneumoniae was analyzed by a sigmoid E (max) model, and there was high correlation between the kill rate and doxycycline concentration (R (2) = 0.986). A one-compartment open model with first-order absorption was adopted and was used to simulate doxycycline pharmacokinetics in porcine plasma. The dynamic time–concentration curve showed that the area under the curve at 24 h (AUC(24 h)) and C (max) (peak concentration) after each drug administration was 1.78–48.4 μg h/ml and 0.16–3.41 μg/ml, respectively. The reduction of M. hyopneumoniae (log(10)CFU/ml) for 1, 2.5, 5, 7.5, 10, 15, 20, and 30 mg/kg body weight was 0.16, 1.29, 1.75, 2.94, 3.35, 3.91, 4.35, and 5.77, respectively, during the entire experiment, respectively. When the dose was >10 mg/kg body weight, continuous administration for 3 days could achieve a bactericidal effect. The correlation coefficient of AUC(24 h)/MIC, C (max)/MIC, and %T > MIC (the cumulative percentage of time over a 24-h period that the drug concentration exceeds the MIC) with antibacterial effect was 0.917, 0.923, and 0.823, respectively. Doxycycline showed concentration-dependent activity, and the value of AUC(24 h)/MIC and C (max)/MIC required to produce a drop of 1 log(10)CFU/ml was 164 h and 9.89, respectively. Frontiers Media S.A. 2019-09-20 /pmc/articles/PMC6763577/ /pubmed/31620004 http://dx.doi.org/10.3389/fphar.2019.01088 Text en Copyright © 2019 Zhang, Mao, Li, Huang, Gu, Shen and Ding http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Pharmacology
Zhang, Huilin
Mao, Chunxiao
Li, Jinju
Huang, Zilong
Gu, Xiaoyan
Shen, Xiangguang
Ding, Huanzhong
Pharmacokinetic/Pharmacodynamic Integration of Doxycycline Against Mycoplasma hyopneumoniae in an In Vitro Model
title Pharmacokinetic/Pharmacodynamic Integration of Doxycycline Against Mycoplasma hyopneumoniae in an In Vitro Model
title_full Pharmacokinetic/Pharmacodynamic Integration of Doxycycline Against Mycoplasma hyopneumoniae in an In Vitro Model
title_fullStr Pharmacokinetic/Pharmacodynamic Integration of Doxycycline Against Mycoplasma hyopneumoniae in an In Vitro Model
title_full_unstemmed Pharmacokinetic/Pharmacodynamic Integration of Doxycycline Against Mycoplasma hyopneumoniae in an In Vitro Model
title_short Pharmacokinetic/Pharmacodynamic Integration of Doxycycline Against Mycoplasma hyopneumoniae in an In Vitro Model
title_sort pharmacokinetic/pharmacodynamic integration of doxycycline against mycoplasma hyopneumoniae in an in vitro model
topic Pharmacology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6763577/
https://www.ncbi.nlm.nih.gov/pubmed/31620004
http://dx.doi.org/10.3389/fphar.2019.01088
work_keys_str_mv AT zhanghuilin pharmacokineticpharmacodynamicintegrationofdoxycyclineagainstmycoplasmahyopneumoniaeinaninvitromodel
AT maochunxiao pharmacokineticpharmacodynamicintegrationofdoxycyclineagainstmycoplasmahyopneumoniaeinaninvitromodel
AT lijinju pharmacokineticpharmacodynamicintegrationofdoxycyclineagainstmycoplasmahyopneumoniaeinaninvitromodel
AT huangzilong pharmacokineticpharmacodynamicintegrationofdoxycyclineagainstmycoplasmahyopneumoniaeinaninvitromodel
AT guxiaoyan pharmacokineticpharmacodynamicintegrationofdoxycyclineagainstmycoplasmahyopneumoniaeinaninvitromodel
AT shenxiangguang pharmacokineticpharmacodynamicintegrationofdoxycyclineagainstmycoplasmahyopneumoniaeinaninvitromodel
AT dinghuanzhong pharmacokineticpharmacodynamicintegrationofdoxycyclineagainstmycoplasmahyopneumoniaeinaninvitromodel